I think this study has the right idea, casting a very wide net using a list of 1348 FDA-approved drugs.In contrast, focusing on one genetic alteration and treating it with one targeted oncology drug has not generally worked for GBM (see link below). This is not surprising given the molecular heterogeneity of GBM, and the fact that most/all of these targeted inhibitors were approved for other cancers and have very little evidence of good CNS penetration.http://www.ncbi.nlm.nih.gov/pubmed/27531351
I know one of the authors personally, will ask for a full paper.
Which paper? The one Michael mentioned is open access. The one that I linked to is not, but I can upload it to the library.